| Status | Suspended |
| Process | STA pre-2018 |
| Referral date | 01 June 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | Gillian Leng |
| Project manager: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 May 2014 |
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of tolevamer for clostridium difficile.. Following an update on the regulatory status of this technology, the manufacturer has informed us that development on tolevamer for clostridium difficile has stopped and there are no plans to seek regulatory approval. Therefore, the appraisal remains suspended. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance